Anti-retroviral therapy, insulin resistance and lipodystrophy

Diabetes, Obesity and Metabolism

Volumn 3, Issue 2, 2001, Pages 67-71

  Gan, Seng Khee ^a   Samaras, Katherine ^a   Carr, Andrew ^a   Chisholm, Donald ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIRETROVIRUS AGENT; ATORVASTATIN; CORTICOSTEROID; DIDANOSINE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAMIVUDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PENTAMIDINE; PROTEINASE INHIBITOR; RETINOIC ACID BINDING PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPODYSTROPHY; MUSCLE ATROPHY; PANCREATITIS; PATHOGENESIS; PNEUMOCYSTOSIS; REVIEW;

EID: 0034877173     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00146.x     Document Type: Review

References (38)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients
3. HIV disease progression in Australia in the time of combination antiretroviral therapies
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
5. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus
6. Indinavir-associated lipodystrophy
7. Visceral abdominal-fat accumulation associated with use of indinavir
8. 'Buffalo hump' in men with HIV-1 infection
9. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease
10. Pathophysiology of visceral fat obesity
11. Medical hazards of obesity
12. Obesity
13. Abdominal fat and insulin resistance in normal and overweight women
14. Pathogenesis of HIV protease inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance
15. Structures and functions of multiligand lipoprotein receptors: Macroptiage scavenger receptors and LDL receptor-related protein (LRP)
16. Surgical implantation of adipose tissue reserves diabetes in lipoatrophic mice
17. Generalized lipodystrophy, congenital and acquired (lipoatrophy)
18. Dunnigan-Kobberling syndrome: An autosomal dominant form of partial lipodystrophy
19. Pushing the envelope on lipodystrophy
20. Genetic exclusion of 14 candidate genes in lipoatrophic diabetes using linkage analysis in 10 consanguineous families
21. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
22. LMNA, encoding lamin A/C is mutated in partial lipodystrophy
23. Banting Lecture: Role of insulin resistance in human disease
24. A syndrome of insulin resistance: Epidemiological and clinical evidence
25. Perspectives in diabetes: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications
26. Adverse effects of antiretroviral therapy
27. A syndrome of lipodystrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
28. Inhibition of adipocyte differentiation by HIV protease inhibitors
29. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
30. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
31. Severe premature coronary artery disease with protease inhibitors
32. Vascular complications associated with HIV protease inhibitors
33. Myocardial infarction in HIV-infected men receiving protease inhibitors
34. Sudden cardiac death in a patient on a 2 years of highly active antiretroviral treatment: A case report
35. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
36. Cholesterol, endothelial function and cardiovascular disease
37. Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities
38. Diabetes mellitus associated with pentamidine use in HIV-infected patients